Kerstin Sander1, Tammaryn Lashley2, Priya Gami2, Thibault Gendron1, Mark F Lythgoe3, Jonathan D Rohrer4, Jonathan M Schott4, Tamas Revesz2, Nick C Fox4, Erik Årstad5. 1. Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK. 2. Institute of Neurology, Department of Molecular Neuroscience, Queen Square Brain Bank, University College London, London, UK. 3. Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK. 4. Institute of Neurology, Department of Neurodegenerative Disease, Dementia Research Centre, University College London, London, UK. 5. Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK. Electronic address: e.arstad@ucl.ac.uk.
Abstract
INTRODUCTION: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [18F]AV-1451 in a range of dementias. METHODS: Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias. RESULTS: [18F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups. DISCUSSION: [18F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.
INTRODUCTION: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [18F]AV-1451 in a range of dementias. METHODS: Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias. RESULTS: [18F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups. DISCUSSION: [18F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.
Authors: Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla Journal: Acta Neuropathol Date: 2017-06-13 Impact factor: 17.088
Authors: Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella Journal: J Cereb Blood Flow Metab Date: 2016-12-22 Impact factor: 6.200
Authors: Anna E Goodheart; Joseph J Locascio; Wesley R Samore; Jessica A Collins; Michael Brickhouse; Aaron Schultz; Alexandra Touroutoglou; Keith A Johnson; Matthew P Frosch; John H Growdon; Bradford C Dickerson; Stephen N Gomperts Journal: Brain Date: 2021-02-12 Impact factor: 13.501
Authors: Corey T McMillan; David J Irwin; Ilya Nasrallah; Jeffrey S Phillips; Meredith Spindler; Katya Rascovsky; Kylie Ternes; Charles Jester; David A Wolk; Linda K Kwong; Virginia M-Y Lee; Edward B Lee; John Q Trojanowski; Murray Grossman Journal: Acta Neuropathol Date: 2016-11-04 Impact factor: 17.088
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Mov Disord Date: 2018-11-23 Impact factor: 10.338
Authors: Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Ann Neurol Date: 2020-09-12 Impact factor: 10.422